NovoCure Limited is a global oncology company that focuses on developing and commercializing innovative therapies for cancer patients. The company’s proprietary technology, Tumor Treating Fields (TTFields), uses electric fields to disrupt cancer cell division and has been shown to improve survival in certain types of cancer. NovoCure has received regulatory approvals for TTFields in multiple countries and is actively conducting clinical trials to expand its use in other cancer types. The company is headquartered in Jersey, with offices in the United States, Switzerland, Japan, and Israel. NovoCure is committed to improving cancer care and enhancing the lives of patients and their families.
